HC Wainwright Brokers Lower Earnings Estimates for Immunic

Immunic, Inc. (NASDAQ:IMUX – Free Report) – Investment analysts at HC Wainwright dropped their FY2026 EPS estimates for Immunic in a report released on Monday, November 16th. HC Wainwright analyst M. Caufield now expects that the company will earn ($3.24) per share for the year, down from their prior estimate of ($3.18). HC Wainwright currently has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.81) per share. HC Wainwright also issued estimates for Immunic’s Q4 2026 earnings at ($0.56) EPS, FY2027 earnings at ($2.27) EPS, FY2028 earnings at ($1.50) EPS and FY2029 earnings at ($0.60) EPS.

Immunic (NASDAQ:IMUX – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20).

A number of other brokerages have also weighed in on IMUX. Zacks Research lowered Immunic from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 10th. Cantor Fitzgerald began coverage on Immunic in a research report on Friday, October 23rd. They issued an “overweight” rating on the stock. Ladenburg Thalmann & Co. Inc. upgraded Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Roth Capital reissued a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.71.

Check Out Our Latest Report on IMUX

Immunic Trading Down 1.6%

Shares of IMUX stock opened at $7.40 on Wednesday. The company’s fifty day simple moving average is $8.29 and its two-hundred day simple moving average is $11.54. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43.

Institutional Trading of Immunic

Several hedge funds have recently made changes to their positions in IMUX. Marshall Wace LLP grew its position in Immunic by 242.8% in the third quarter. Marshall Wace LLP now owns 359,319 shares of the company’s stock worth $3,342,000 after acquiring an additional 254,503 shares in the last quarter. State Street Corp increased its stake in Immunic by 36.9% during the third quarter. State Street Corp now owns 83,859 shares of the company’s stock worth $780,000 after acquiring an additional 22,600 shares during the last quarter. Aberdeen Group plc increased its stake in Immunic by 32.3% during the third quarter. Aberdeen Group plc now owns 1,090,427 shares of the company’s stock worth $10,141,000 after acquiring an additional 266,034 shares during the last quarter. Alps Advisors Inc. raised its position in Immunic by 28.0% during the third quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after purchasing an additional 3,870 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its position in Immunic by 21.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock valued at $69,000 after purchasing an additional 1,400 shares during the period. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Top Immunic Stories

These are some of the IMUX stories that stood out recently:

  • Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to a loss of $0.56 from a loss of $0.68, and its FY2027 estimate to a loss of $2.27 from $2.47. The firm maintained a Buy rating. MarketBeat analyst estimates
  • Neutral Sentiment: A report highlights Immunic’s approaching December multiple-sclerosis readout. Positive results could support the shares, while disappointing data could weigh on them; the article does not report results yet. Immunic Nears Multiple Sclerosis Readout
  • Negative Sentiment: Other forecast revisions point to continuing uncertainty around costs and losses: HC Wainwright slightly increased projected losses for FY2026, FY2028, and FY2029, while Brookline lowered its Q4 and FY2026 EPS estimates more substantially. These cuts may add pressure as investors assess Immunic’s funding needs and development progress. MarketBeat analyst estimates

Immunic Company Profile

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Featured Articles

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.